CONDENSED INTERIM FINANCIAL STATEMENTS

For the Three Months Ended March 31, 2021 and 2020

(Expressed in Canadian Dollars – unaudited)

Condensed Interim Statements of Financial Position

(Expressed in Canadian Dollars - unaudited)

	Note	March 31, 2021		December 31, 2020	
ASSETS					
Current					
Cash		\$	736,956	\$	763,677
Marketable securities	3		1,250		1,750
Receivables			-		-
TOTAL ASSETS		\$	738,206	\$	765,427
LIABILITIES AND SHAREHOLDERS' EOUITY Current					
		\$	22,348	\$	18,599
Current	3	\$	22,348 12,000	\$	
Current Accounts payable and accrued liabilities	3	\$		\$	18,599 12,000 30,599
Current Accounts payable and accrued liabilities Loans	3	\$	12,000	\$	12,000
Current Accounts payable and accrued liabilities Loans TOTAL LIABILITIES	3		12,000		12,000
Current Accounts payable and accrued liabilities Loans TOTAL LIABILITIES Shareholders' Equity			12,000 34,348		12,000 30,599
Current Accounts payable and accrued liabilities Loans TOTAL LIABILITIES Shareholders' Equity Share capital	4		12,000 34,348 4,281,875		12,000 30,599 4,281,875 194,619
Current Accounts payable and accrued liabilities Loans TOTAL LIABILITIES Shareholders' Equity Share capital Contributed surplus	4		12,000 34,348 4,281,875 194,619		12,000 30,599 4,281,875

Approved on behalf of the Board:

<u>"Leighton Bocking"</u> Leighton Bocking, Director <u>"Kyle Stevenson"</u> Kyle Stevenson, Director

Condensed Interim Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars - unaudited)

	Note	Three months ended March 31, 2021		_	Three months ended arch 31, 2020
Consulting, corporate and administrative fees Transfer and filing fees Professional fees Office		\$	23,625 5,100 1,721 24	\$	22,500 2,081 264 180
Other			(30,470)		(25,025)
Unrealized loss on marketable securities	3		(500)		-
Net and comprehensive loss for the period		\$	(30,970)	\$	(25,025)
Loss per share		\$	(0.00)	\$	(0.00)
Weighted average number of common shares outstanding			9,979,407		9,979,407

Condensed Interim Statements of Changes in Shareholders' Equity (Expressed in Canadian Dollars – unaudited)

	Number of					Total
	Common	Share	Contributed		Shar	eholders'
	Shares	Capital	Surplus	Deficit		Equity
Balance, December 31, 2019	9,979,407	\$ 4,281,875	\$ 326,466	\$ (3,757,118)	\$	851,223
Net and comprehensive loss for the period	-	-	-	(25,025)		(25,025)
Balance, March 31, 2020	9,979,407	4,281,875	326,466	(3,782,143)		826,198
Balance, December 31, 2020	9,979,407	4,281,875	194,619	(3,741,666)		734,828
Net and comprehensive loss for the period	-	-	-	(30,970)		(30,970)
Balance, March 31, 2021	9,979,407	\$ 4,281,875	\$ 194,619	\$ (3,772,636)	\$	703,858

Statements of Cash Flows (Expressed in Canadian Dollars – unaudited)

	Th Ma	Three months ended March 31, 2020		
Cash provided by (used in):				
Operating activities				
Net loss for the period	\$	(30,970)	\$	(25,025)
Items not affecting cash: Unrealized loss on marketable securities		500		-
Changes in non-cash working capital items: Receivables Accounts payable and accrued liabilities		- 3,749		(1,246) (1,271)
Net cash used in operating activities		(26,721)		(27,542)
Change in cash		(26,271)		(27,542)
Cash and Cash Equivalents, beginning of the year		763,677		867,595
Cash and Cash Equivalents, ending of the year	\$	736,956	\$	840,053

DATINVEST INTERNATIONAL LTD. Notes to the Condensed Interim Financial Statements For the Three Months Ended March 31, 2021 (Expressed in Canadian Dollars – unaudited)

1. <u>Nature of Operations and Going Concern</u>

Datinvest International Inc. (the "Company") was incorporated under the British Columbia Company Act on May 1, 1987. The Company was unable to meet Tier Maintenance Requirements pursuant to the policies of the Exchange and was designated as Inactive on September 28, 2001. The Company's shares are trading under the symbol DAI.H and are regulated by the NEX policies.

The address of the Company's corporate office and principal place of business is Suite 918, 1030 West Georgia Street, Vancouver, British Columbia, Canada V6E 2Y3.

On March 31, 2021, the Company signed a non-binding letter of intent with GVB BioPharma and Irwin Naturals to complete a business combination (Note 7).

On March 11 2020, the World Health Organization characterized the outbreak of a strain of the novel coronavirus ("COVID-19") as a pandemic which has resulted in a series of public health and emergency measures that have been put in place to combat the spread of the virus. The duration and impact of COVID-19 is unknown at this time and it is not possible to reliably estimate the impact that the length and severity of these developments will have on the financial results and condition of the Company in future periods, including the possible impact on future financing opportunities.

2. <u>Summary of Significant Accounting Policies</u>

These unaudited condensed interim financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34, *Interim Financial Reporting*, as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain information and footnote disclosure normally included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") have been omitted or condensed, and therefore these unaudited condensed interim financial statements should be read in conjunction with the Company's December 31, 2020 audited annual financial statements and the notes to such financial statements.

The preparation of the Company's unaudited condensed interim financial statements in accordance with IFRS requires the Company to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

These unaudited condensed interim financial statements are based on the IFRS issued and effective as of May 19, 2021, the date these condensed interim financial statements were authorized for issuance by the Company's Board of Directors, and follow the same accounting policies and methods of computation as the most recent annual consolidated financial statements.

DATINVEST INTERNATIONAL LTD. Notes to the Condensed Interim Financial Statements For the Three Months Ended March 31, 2021 (Expressed in Canadian Dollars – unaudited)

3. <u>Marketable Securities</u>

The Company's other investments, which are classified as FVTPL have been valued at their market prices.

March 3	61, 2021	December 31, 2020	
Cost	Market	Cost	Market
\$10,000	\$1,250	\$10,000	\$1,750

On August 12, 2010, the Company received 250,000 shares of Orestone Mining Corp. in settlement of the \$25,000 owed by Intuitive Exploration Inc., which was acquired by Orestone on June 3, 2010. On September 18, 2012 Orestone consolidated its shares on 1 for 4 basis and as a result the Company now holds 12,500 shares. The Company classifies these shares as FVTPL and, accordingly; any unrealized gains and losses in fair value are included in net income or loss for the period.

4. Share Capital and Contributed Surplus

Share Capital

Authorized: Unlimited common shares without par value

As at March 31, 2021, the Company had 9,979,407 common shares outstanding (December 31, 2020 – 9,979,407).

Stock Options

A continuity schedule of the Company's outstanding stock options for the three months ended March 31, 2021 and 2020 are as follows:

	March 31, 2021			March 31, 2020			
	Number outstanding	Weighted average exercise price		0		d average rcise price	
Outstanding, beginning of period	175,000	\$	0.41	500,000	\$	0.41	
Granted	-		-	-		-	
Outstanding and exercisable, end							
of period	175,000	\$	0.41	500,000	\$	0.41	

At March 31, 2020, the Company had outstanding stock options exercisable to acquire common shares of the Company as follows:

				Weighted average remaining contractual
Expiry date	Options outstanding	Exerc	ise price	life (in years)
March 16, 2023	175,000	\$	0.41	1.96

DATINVEST INTERNATIONAL LTD. Notes to the Condensed Interim Financial Statements For the Three Months Ended March 31, 2021 (Expressed in Canadian Dollars – unaudited)

5. Fair Value Measurement

Measurement of the fair value of financial instruments is made under a fair value hierarchy comprising three levels reflecting the significance of the inputs used in making the measurements, described as follows:

Level 1 - quoted prices in active markets for identical assets or liabilities.

Level 2 - inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - inputs for the asset or liability that are not based on observable market data.

At March 31, 2021 and December 31, 2020, the levels in the fair value hierarchy into which the Company's financial assets and liabilities measured and recognized in the balance sheet at fair value are categorized are as follows:

	2020 Level 1			2019 .evel 1
Cash	\$	736,956	\$ 7	763,677
Marketable securities	\$	1,250	\$	1,750

6. <u>Related Party Transactions</u>

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers.

During the three months ended March 31, 2021 and 2020, cash compensation of key management personnel and share-based compensation were \$nil.

7. <u>Business Combination</u>

On March 31, 2021, the Company signed a non-binding letter of intent with GVB Biopharma ("GVB") and Irwin Naturals ("Irwin") to complete a business combination (the "Transaction"), subject to regulatory approval. The Transaction will result in a reverse-takeover of the Company and, upon completion of the Transaction, the Companies will become subsidiaries of the Company and the combined entity (the "Resulting Issuer") will continue to carry on the businesses of Irwin and GVB. The closing of the Transaction will be subject to a number of terms and conditions, including the receipt of all necessary regulatory and third-party consents and approvals, the listing of the Resulting Issuer on the Canadian Securities Exchange (the "CSE") and the concurrent delisting of the Company from the TSX Venture Exchange (the "TSXV"). Each of the Company, Irwin and GVB are arm's length from one another. The LOI is expected to be superseded by a definitive agreement (the "Definitive Agreement") to be signed by the parties on or before June 30, 2021.